Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5622471 | 1.00 | SLC17A5 (0.64) | SLC17A5MEN1KMT2AMDM2KDM4E | |
| SCHEMBL5276812 | 1.00 | SLC17A5 (0.64) | SLC17A5MEN1KMT2AMDM2KDM4E | |
| SCHEMBL20281115 | 0.89 | SLC17A5 (0.61) | SLC17A5MEN1KMT2AMDM2MDM4 | |
| SCHEMBL14456737 | 0.89 | SLC17A5 (0.80) | SLC17A5MEN1KMT2AKDM4ELCK | |
| SCHEMBL5622589 | 0.89 | SLC17A5 (0.80) | SLC17A5MEN1KMT2AKDM4ELCK | |
| SCHEMBL5051765 | 0.88 | SLC17A5 (0.58) | SLC17A5MEN1KMT2AMDM2KDM4E | |
| SCHEMBL5622718 | 0.84 | MEN1 (0.62) | MEN1KMT2AKDM4ELCKALDH1A1 | |
| SCHEMBL38666359 | 0.82 | MDM2 (0.53) | SLC17A5MEN1KMT2AMDM2ALDH1A1 | |
| SCHEMBL25259834 | 0.81 | MDM2 (0.53) | SLC17A5MDM2MDM4TP53 | |
| SCHEMBL22444667 | 0.81 | MDM2 (0.53) | SLC17A5MDM2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161807-A1 | Method for manufacturing optically pure coumaryl amino acids and the novel coumaryl aminoacids thus obtained | INSERM (INSTITUT NATIONAL DE LA SANT'E ET DE LA RECHERCHE MEDICALE (FR) | 2007-07-12 | — | — | US | claimed |
| EP-1559712-A1 | A method for manufacturing optically active coumaryl amino acid salts and the coumaryl aminoacid salts thus obtained | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2005-08-03 | — | — | EP | claimed |
| US-20070161807-A1 | Method for manufacturing optically pure coumaryl amino acids and the novel coumaryl aminoacids thus obtained | INSERM (INSTITUT NATIONAL DE LA SANT'E ET DE LA RECHERCHE MEDICALE (FR) | 2007-07-12 | — | — | US | disclosed |
| US-20070161807-A1 | Method for manufacturing optically pure coumaryl amino acids and the novel coumaryl aminoacids thus obtained | INSERM (INSTITUT NATIONAL DE LA SANT'E ET DE LA RECHERCHE MEDICALE (FR) | 2007-07-12 | — | — | US | disclosed |
| US-20070161807-A1 | Method for manufacturing optically pure coumaryl amino acids and the novel coumaryl aminoacids thus obtained | INSERM (INSTITUT NATIONAL DE LA SANT'E ET DE LA RECHERCHE MEDICALE (FR) | 2007-07-12 | — | — | US | disclosed |
| EP-1711483-A2 | A METHOD FOR MANUFACTURING OPTICALLY PURE COUMARYL AMINO ACID SALTS AND THE COUMARYL AMINO ACID SALTS THUS OBTAINED | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005075448-A2 | A METHOD FOR MANUFACTURING OPTICALLY PURE COUMARYL AMINO ACIDS SALTS AND THE COUMARYL AMINO ACID SALTS THUS OBTAINED | INSTITUT NATIONAL DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2005-08-18 | — | — | WO | disclosed |
| EP-1559712-A1 | A method for manufacturing optically active coumaryl amino acid salts and the coumaryl aminoacid salts thus obtained | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161807-A1 | Method for manufacturing optically pure coumaryl amino acids and the novel coumaryl aminoacids thus obtained | CRYAA, BCAT2, BCAT1 | SLC17A5 1829/4885MEN1 4557/4885KMT2A 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.